Clinical Trial

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

Study acronym: CORINNE-PI
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a prospective, randomised, controlled, multicentre study to compare the efficacy and safety between continuous or intermittent extension of adjuvant pyrotinib in invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-06-09; most recent amendment 2025-11-14.
Status change: Not Yet Recruiting → Recruiting 2023-11-18
Trial Details
NCT Number NCT05910398
Lead Sponsor RenJi Hospital
Conditions Breast Cancer Invasive
Enrollment 488 participants
Start Date 2023-06-01
Primary Completion 2030-04 (estimated)
Study Completion 2030-08 (estimated)
Updated on ClinicalTrials.gov 2025-11-18